ANR 16.4% 5.6¢ anatara lifesciences ltd

Ann: Anatara Lifesciences announces leadership change, page-3

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 13 Posts.
    lightbulb Created with Sketch. 10
    I'm not sure how I feel about Steve leaving us. The only time I met him was on the very day Zoetis handed back the license for Detach. Steve was here in Perth for a shareholders meeting. He had only been in the job for 2 minutes and I was impressed by how calm and measured he was whilst the rest of us thought this was the end of the world. So I have been a supporter of his ever since. Am I guilty of looking through rose tinted glasses ever since that first impression?

    Having said that, the last 3 and a half years with Steve as CEO have not been the best for us. One of the disappointing things to me is that we never met any of our time frames whether that be the results of tests in the lab, or the results of field studies or any announcements. Not a single one I don't think. It seems as though everything has always been delayed. Though in these unprecedented times I'm not sure how much of the blame can be put on Steve or if that is just the way it is at the moment.

    Another disappointing thing has been the inability of management to find any takers for Detach, which I have written about before. Coincidently, following the quarterly report last week which once again made no mention of our animal health products, I sent an email to Steve. He responded this week saying that nothing much has been said about Detach because there has been nothing much to say. However, he says that "we should be assured that we continue to pursue opportunities to further develop/commercialise our animal health assets" and that "we are in discussions with animal feed companies and poultry producers who are evaluating our new formulations". How long have we been hearing that line for (refer to my previous posting)?

    I note that the board are not going to appoint a new CEO at this time. Perhaps someone can tell me if I should read anything sinister into that or not. I guess if nothing else, the money we save on a CEO salary will help cover the cost of the salaries for the two new management appointees.
 
watchlist Created with Sketch. Add ANR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.